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Objectives: To evaluate the accuracy of transrectal ultrasound-guided (TRUS) biopsy, 
diffusion-weighted (DW) magnetic resonance imaging (MRI), 11C-choline (CHOL) positron 
emission tomography (PET), and 18F-fluorodeoxyglucose (FDG) PET in predicting the 
prostatectomy Gleason risk (GR). 
 
Methods: The study included 21 patients who underwent TRUS biopsy and multi-technique 
imaging before radical prostatectomy. Values from five different tests (TRUS biopsy, DW 
MRI, CHOL PET, FDG PET, and combined DW MRI / CHOL PET) were correlated with 
the prostatectomy GR using Spearman’s ρ. Tests that were found to have significant 
correlations were used to classify patients into GR groups. 
 
Results: The following tests had significant correlations with prostatectomy GR: TRUS 
biopsy (ρ = 0.617, P = 0.003), DW MRI (ρ = –0.601, P = 0.004), and combined DW MRI / 
CHOL PET (ρ = –0.623, P = 0.003). CHOL PET alone and FDG PET only had weak 
correlations. The correct GR classification rates were 67% with TRUS biopsy, 67% with DW 




Conclusions: DW MRI and combined DW MRI / CHOL PET have significant correlations 
and high rates of correct classification of the prostatectomy GR, the strength and accuracy of 
which are comparable with TRUS biopsy. 
 
Keywords: 






 Accurate determination of the Gleason score is essential for prostate cancer 
management. 
 DW MRI ± CHOL PET correlated significantly with prostatectomy Gleason score. 
 These correlations are similar to that between TRUS biopsy and prostatectomy. 
Introduction 
 
The Gleason score is the most commonly used pathological grading system in prostate 
carcinoma. It has been more than 40 years since its inception [1], yet it remains one of the 
most powerful prognostic factors in prostate carcinoma [2, 3]. It is central to stratifying 
patients into risk groups and in determining the management in patients with prostate 




Transrectal ultrasound-guided (TRUS) biopsies are commonly used to determine the Gleason 
score prior to definitive management [6]. TRUS biopsies were shown to be acceptably 
accurate [7] in predicting the Gleason score on prostatectomy specimens, and as such, have 
become part of the routine work-up of men with suspected prostate cancer [4, 5]. 
 
There are several shortcomings to TRUS biopsy, however. Firstly, while it is acceptably 
accurate, it should be recognised that there may still be discrepancies in 25–30% of cases [7]. 
Secondly, while TRUS biopsy is generally accepted to have a good safety profile, it is still an 
invasive procedure, with significant complications reported in up to 6% of patients [8, 9]. 
Thirdly, up to 15–31% of patients may need repeated biopsies simply because the initial 
TRUS biopsy missed the regions that contained carcinoma [10]. Patients undergoing active 
surveillance also need repeated biopsies [4]. 
 
Novel imaging techniques have been proposed for either augmenting or supplanting TRUS 
biopsies for prognostication in patients with prostate carcinoma. These imaging techniques 
include diffusion-weighted (DW) MRI [11-13], magnetic resonance spectroscopy (MRS) [14], 
dynamic contrast enhanced (DCE) MRI [15], 11C-choline (CHOL) PET [16, 17], and 18F-
fluorodeoxyglucose (FDG) PET [18]. This study investigates three of these novel imaging 
techniques: DW MRI, CHOL PET and FDG PET. The biological mechanisms of how these 
imaging techniques differentiate between aggressive pathological conditions and less 
aggressive ones have been extensively investigated. 
 
DW MRI obtains images that are dependent upon the random movement of water molecules 
(Brownian motion) in the imaged tissues [19]. This reflects the diffusion of water in the 
interstitial space, providing information on the biophysical properties of the tissue, including 
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tissue architecture and cell density. The diffusion properties of the tissue examined can be 
quantified by calculating the apparent diffusion coefficient (ADC), which has been found to 
correlate significantly with cell density [19, 20]. The ADC declines as the glandular 
architecture is replaced more and more by tightly packed cancer cells, which is the case with 
higher Gleason score cancers. 
 
CHOL PET obtains images that are dependent upon the accumulation of CHOL into 
cells [21]. CHOL is a radiotracer based on choline, an essential component of the cell 
membrane. Choline is taken up into cells by the choline transport system and then 
phosphorylated by choline kinase to phosphorylcholine. Prostate cancer cells have a high 
uptake of choline into cells, possibly due to a higher proliferation rate. CHOL PET 
standardised uptake values (SUV) have been found to correlate significantly with several 
immunohistochemical markers of malignancy and aggressiveness, including choline kinase  
expression [22] and MIB-1/Ki-67 labelling index [16]. 
 
FDG PET allows the assessment of the metabolic state of malignant lesions by imaging the 
accumulation of FDG into tumour cells [23]. FDG is a glucose derivative where the hydroxyl 
function in position 2 is replaced by a radioactive fluorine isotope. FDG is taken up by 
glucose transporters into the cell and phosphorylated via hexokinase. Because of the missing 
hydroxyl function, further metabolism is not possible, and because of the negative charge, the 
phosphorylated FDG cannot cross the cell membrane, leading to trapping in the cell. FDG 
PET SUV has been found to be correlated with glucose transporter expression, which is 




The fact that imaging is non-invasive provides it with important advantages over TRUS 
biopsy. While many prior studies have shown novel imaging techniques to have good 
correlations with the Gleason score, few have shown that imaging is as good as the current 
standard of TRUS biopsy. Our study aims to investigate the accuracy of DW MRI, CHOL 
PET and FDG PET, and compares them to the current standard of TRUS biopsy. 
 
Materials and Methods 
 
Study design and patient population 
 
This is an analysis of data from a prospective single institution study of 30 patients recruited 
between September 2008 and March 2011 with histopathologically proven adenocarcinoma 
of the prostate with intermediate to very high-risk disease [4]. All patients provided written 
informed consent, and the study was approved by the institutional ethics committee. All 
patients underwent standard diagnostic and staging investigations before recruitment, 
including serum PSA, TRUS biopsy, whole body skeletal scintigraphy and CT. None of the 
patients had any treatment for prostate cancer before recruitment into this study. Eligibility 
criteria included expected survival longer than 3 months, Karnofsky performance status ≥ 70, 
no known nodal or distant metastases, and no contraindications to PET or MRI. All patients 
underwent pelvic MRI, pelvic CHOL PET/CT, and whole-body FDG PET/CT at least 2 
weeks after the TRUS biopsy. DW MRI was not mandated in the original trial protocol, but 
was also performed with the standard MRI sequences in 24 patients. The patients then 
underwent radical prostatectomy within 4 weeks of MRI and PET. Patients who did not have 
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DW MRI or who had significant imaging artefact that compromised their interpretation were 
excluded from the final analysis. 
 
The pathologist’s interpretation of the prostatectomy specimen was used as the reference 
standard. Five index tests were evaluated: TRUS biopsy, DW MRI, CHOL PET, FDG PET, 
and combined DW MRI / CHOL PET. 
 
Imaging acquisition protocols 
 
Synthesis of CHOL and FDG was performed on site, using an in-house cyclotron (Ion Beam 
Applications SA, Belgium) and radiochemistry laboratories [24]. CHOL and FDG PET/CT 
imaging protocols have previously been described [21, 25]. CHOL and FDG PET images had 
fields of view (FOV) of 576 mm x 576 mm and voxel sizes of 4 mm x 4 mm x 4 mm. 
 
Magnetic resonance imaging was performed on a 3-Tesla Magnetom Verio system (Siemens, 
Erlangen, Germany) with an external 32-channel body-array coil. Sequences that were 
analysed in this study include multiplanar 2D T2W turbo spin-echo (TSE), 3D T2W sampling 
perfection with application optimised contrasts using different flip angle evolutions (SPACE), 
and DW sequences. The following parameters were used in the TSE sequences: repetition 
time (TR) 4200 ms, echo time (TE) 89 ms, field of view (FOV) 170 mm x 170 mm, and 
voxel size 1.9 mm x 1.9 mm x 4.4 mm. The following parameters were used in the SPACE 
sequence: TR 1700 ms, TE 102 ms, FOV 200 mm x 200 mm, and voxel size 1.3 mm x 1.3 
mm x 1 mm. The following parameters were used in the DW MRI sequence: TR 4500 ms, 
TE 97 ms, FOV 233 mm x 233 mm, voxel size 1.2 mm x 1.2 mm x 4.4 mm, and b values: 0, 






where S1 is the signal intensity of a voxel after application of a diffusion gradient and S0 is 
the echo magnitude without diffusion gradients applied (b = 0 s/mm2). Diffusion sensitivity 
is determined by the difference between b1 and b0. 
 
Pathological specimen preparation and interpretation 
 
The prostate was step-sectioned into 4-mm transverse slices, perpendicular to its posterior 
surface, as previously described. An experienced genitourinary pathologist (DC, 19 years’ 
experience) reviewed the specimen and assigned a Gleason score as per the International 
Society of Urological Pathology (ISUP) consensus criteria [2]. This prostatectomy-defined 
Gleason score was used as the reference standard. The pathologist outlined each tumour focus 
on the histological sections and then imaged them directly on a flat-bed device. 
 
The TRUS biopsy reports were reviewed. Where tertiary patterns were reported, the overall 
Gleason score was taken as the sum of the primary pattern and the highest grade pattern as 






All images were co-registered and analysed using Mim Maestro (MIM Software Inc., 
Cleveland, OH, USA). The SPACE MRI sequence was used as the primary dataset. The 
prostatectomy specimen digital images were divided up, stacked, and reorientated to match 
the MRI slices (Fig. 1). The DW MRI, CHOL PET and FDG PET acquisitions were manually 
co-registered with the MRI using rigid body transformation as secondary datasets (Fig. 1). 
 
Extraction of quantitative information from the scans 
 
One representative region of interest was defined for each imaging technique for each patient 
from whom voxel intensity data were extracted. 
 
The DW MRI region of interest was defined as the visible peripheral zone tumour, from 
which the mean ADC (mm2/s) was taken. This contour was defined by two experienced 
genitourinary radiologists (*BLINDED*, 15 and 12 years’ experience, respectively) who 
independently reviewed the MRIs. The radiologists were aware that all patients had biopsy-
proven prostate cancer, but were blinded to all other clinical information. They reviewed all 
of the MRI sequences, and then using only DW MRI, contoured the regions inside the 
peripheral zones that they thought were likely to be involved by tumour. The two 
radiologists’ contours were combined by Boolean addition to form a single set of contours 
and then compared with the pathological specimens (Fig. 1). Contours that did not overlap 
with tumour on the prostatectomy specimens were removed. Where no discrete lesion was 
visible on the DW MRI, the region of interest was defined as the prostate peripheral zone. 
 
The CHOL PET and FDG PET regions of interest were defined as the peripheral zone, from 
which the maximum SUV (SUVmax) was taken for each acquisition. A radiation oncologist 
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contoured the prostate peripheral zone onto the primary dataset for each patient and then had 
these contours reviewed by two genitourinary radiologists. 
 
An “uninvolved peripheral zone” contour was created by Boolean subtraction of the DW 
MRI region of interest contour with 0.5-mm expansion from the peripheral zone contour 




Gleason scores were categorised into three groups: Gleason risk (GR) 1 corresponding to 
Gleason score 6, GR 2 corresponding to Gleason score 7, and GR 3 corresponding to Gleason 
scores 8–10. The prostatectomy specimen GR was taken as the reference standard against 
which the other tests were compared. 
 
Five index tests were evaluated to determine their ability to predict the prostatectomy 
specimen GR: (1) TRUS biopsy GR, (2) mean ADC score from DW MRI, (3) SUVmax from 
CHOL PET, (4) SUVmax from FDG PET, and (5) combined DW MRI and CHOL PET 
(calculated by dividing the mean ADC score [from DW MRI] by the SUVmax [from CHOL 
PET]). 
 
Spearman’s ρ was used to determine the correlations between the predictive tests described 
above and the prostatectomy specimen GR. The strengths of these correlations were labelled 
using conventional statistical criteria: 0-0.19 was regarded as very weak, 0.2-0.39 as weak, 
0.40-0.59 as moderate, 0.6-0.79 as strong and 0.8-1 as very strong correlation [26]. Predictive 
tests that were found to have significant correlations were separated into GR groups based on 
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arbitrarily defined cut-off values. The accuracy of the predictive tests for classifying the 
patients into the correct GR groups was evaluated. The accuracy of classification was 
compared between the different tests using two-tailed McNemar’s tests. Scatterplots were 
used to illustrate the relationships between the predictive tests and the prostatectomy GR.  
 
The mean DW MRI ADC values of the regions of interest were compared with the 
uninvolved peripheral zone using a paired, two-tailed t-test. Statistical tests were performed 




Twenty one patients were included in the final analyses owing to 6 patients not having DW 
MRIs and 3 patients having significant susceptibility artefacts (caused by prosthetic hips) on 
the DW MRIs. Two patients did not have identifiable lesions on the DW MRIs, therefore 
their entire peripheral zones were used as the regions of interest. The index lesions were in 
the peripheral zones in all 21 patients on the prostatectomy specimens. The patient 
characteristics have been listed in Table 1. 
 
There was a significant, strongly positive correlation between TRUS biopsy GR and 
prostatectomy GR (ρ = 0.617, P = 0.003; Table 2). There was a significant, strongly negative 
correlation between the DW MRI mean ADC and prostatectomy GR (ρ = –0.601, P = 0.004). 
There was a non-significant, weak positive correlation between CHOL PET SUVmax and 
prostatectomy GR (ρ = 0.348, P = 0.122). There was a non-significant, weak positive 
correlation between FDG PET SUVmax and prostatectomy GR (ρ = 0.204, P = 0.375). The 
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combination of DW MRI and CHOL PET had a significant strongly negative correlation with 
prostatectomy GR (ρ = –0.623, P = 0.003). 
 
The cut-off values for classifying GR groups for each type of predictive test are shown in 
Table 3. Using these values, TRUS biopsy correctly classified 14 out of 21 patients (67%), 
DW MRI correctly classified 14 out of 21 patients (67%), and the combination of DW MRI 
and CHOL PET correctly classified 16 out of 21 patients (76%). The differences between the 
three different combinations of these classification rates were not statistically significant (P = 
0.69, 0.73, and 1.0). Scatterplots showing the relationships between the predictive tests and 
the prostatectomy GR are shown in Fig. 2. 
 
The mean DW MRI ADCs were significantly lower in the regions of interest ([1049 ± 315] × 





The main findings in this study are that DW MRI and combined DW MRI / CHOL PET 
correlate significantly with the prostatectomy GR, and have high rates of correct 
classification of the prostatectomy GR. 
 
Many previous studies have shown that DW MRI has a significant correlation with Gleason 
score. Bittencourt et al performed a study of 24 patients, comparing DW MRI ADC values 
with prostatectomy Gleason score [11]. They found a significant negative correlation between 
the mean ADC of suspicious lesions and Gleason score (Pearson’s r = –0.63, P < 0.01). 
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Yamamura et al performed a study of 50 patients, comparing DW MRI ADC with TRUS 
biopsy Gleason score [12]. There was a significant negative correlation between the ADC 
value and the Gleason score on TRUS biopsy (Spearman’s ρ = –0.405, P = 0.001). Turkbey 
et al performed a study of 48 patients, comparing DW MRI ADC with TRUS biopsy Gleason 
score and D’Amico clinical risk score [13]. They found a significant negative correlation 
between the mean ADC and the TRUS biopsy Gleason score (Spearman’s ρ = –0.60, P = 
0.003), and the D’Amico clinical risk score Spearman’s ρ = –0.69, P < 0.0001). 
 
Several studies have also investigated relationships between CHOL PET SUV and Gleason 
score. Piert et al performed a study of 14 patients, comparing tumour to background CHOL 
PET SUV ratios with prostatectomy Gleason scores [16]. They found significantly higher 
tumour to background SUV ratios in high Gleason score lesions (Gleason ≥ 4 + 3) versus 
lower Gleason score lesions (Gleason ≤ 3 + 4). Park et al compared DW MRI, CHOL PET, 
and the combination of the two techniques with prostatectomy Gleason scores in a study of 
17 patients [17]. They found significant differences between Gleason ≥ 3 + 4 cancers versus 
Gleason ≤ 3 + 3 cancers using DW MRI, CHOL PET, or the combination of the two 
techniques. 
 
This study adds to the literature in several important ways. The prostatectomy specimen was 
used to define the GR in this study, as opposed to just using the TRUS biopsy as was used in 
some of the previous studies. This is important because the TRUS biopsy is an imperfect test, 
with discrepancies with the prostatectomy GR in 25–30% of patients [7]. The accuracy of 
TRUS biopsy was also evaluated in this study, which provides an important comparison with 
routine clinical practice. Most clinicians accept the accuracy of TRUS biopsy and in fact rely 
on it to make initial treatment decisions. Our study confirms the results from larger studies [7] 
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of the accuracy of TRUS biopsy, and importantly, shows that imaging can produce results 
that are at least comparable to the TRUS biopsy. 
 
Furthermore, this study shows that multi-technique imaging with both DW MRI and CHOL 
PET may possibly be better than either imaging technique alone for predicting the Gleason 
score (although this study was not powered to detect a statistically significant difference). 
This is a subject that has not as yet been extensively explored [17]; therefore this study may 
provide an impetus for future research. 
 
This study does have a number of limitations. First, all of the patients in this study had index 
lesions in the peripheral zone; therefore the analyses were limited to classifying peripheral 
zone lesions. Primary transition zone carcinomas have been shown to have different DW 
MRI characteristics from peripheral zone carcinomas [27], however this was not investigated 
in this study because none of the patients in this cohort had primary transition zone index 
lesions. Second, the cut-off points for classifying patients into GR groups were chosen to 
maximise agreement, and therefore have an element of bias. These cut-off points need to be 
validated in a prospective study before conclusions can be drawn about their true accuracy. 
Third, most of the patients had GR 2 (Gleason score 7) disease on their prostatectomy 
specimens. The uneven distribution of patients makes it difficult to achieve statistical 
significance in a small study like this. Fourth, all of the patients in this study had acinar 
adenocarcinomas. Non-acinar carcinomas account for 5–10% of carcinomas that originate in 
the prostate, and identifying these histologies may have important implications for the 
prognosis and management of these patients [28]. It is unclear whether or not these 
histologies can be identified using imaging. Fifthly, the b values and other MRI parameters 
used in this study would likely make the ADC values reported in this study non-generalisable 
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to other centres using different MRI parameters. Similarly, the PET imaging parameters may 
also make the SUV values reported here non-generalisable to other centres. Lastly, both 
CHOL and FDG PET may be limited by poor spatial resolution and the partial volume 
effect [29]. This means that smaller, high-grade lesions may be falsely classified as lower 
grade due to the intrinsic limitations of PET. This factor needs to be taken into account when 
interpreting these results. 
 
The main implication of this study is that certain types of imaging may be able to augment 
TRUS biopsy in the prognostication of prostate carcinoma. DW MRI may be useful for this 
purpose, and the combination of DW MRI and CHOL PET may possibly be better. This 
would be useful in many situations. In patients with low-risk prostate cancer on active 
surveillance, imaging may provide a non-invasive means of detecting Gleason score 
progression, and thus may reduce or obviate the need for repeated biopsies. Patients who are 
selected for radical radiotherapy may be more appropriately selected for different durations of 
androgen deprivation therapy based on more accurate determinations of their risk groups. If a 
future study shows that imaging can reliably distinguish between cancerous and benign 
prostate glands, imaging may be able to replace TRUS biopsies in many situations. 
 
In conclusion, DW MRI and combined DW MRI / CHOL PET have significant correlations 
with the prostatectomy GR and high rates of correct classification of the prostatectomy GR. 
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Table 1. Patient characteristics 
 
Characteristic Mean (range) 
 Age 61 (45-73) 
 PSA (ng/ml) 





Mean ± SD 
 DW MRI mean ROI ADC (mm2/s) [1049 ± 315] × 10-6 
 DW MRI mean uninvolved PZ ADC (mm2/s) [1498 ± 213] × 10-6 
 CHOL PET PZ SUVmax 3.29 ± 1.04 
 FDG PET PZ SUVmax 3.15 ± 0.921 
 
   
 
n = 21 % 
T stage 
  pT2c 9 43 
pT3a 8 38 
pT3b 4 19 
N stage 
  pNx 10 48 
pN0 10 48 
pN1 1 5 
M stage 
  M0 21 100 
M1 0 0 
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Prostatectomy Gleason score   
 6 3 14 
3+4=7 6 29 
4+3=7 7 33 
8 1 5 
9 4 19 
TRUS biopsy Gleason score 
  6 3 14 
3+4=7 5 24 
4+3=7 5 24 
8 4 19 
9 4 19 
Abbreviations: DW MRI, diffusion-weighted magnetic resonance imaging; ROI, region of 
interest; ADC, apparent diffusion coefficient; PZ, peripheral zone; CHOL, 11C-choline; FDG, 
18F-fluorodeoxyglucose; PET, positron emission tomography; SUVmax, maximum 




Table 2. Agreement between TRUS GR and prostatectomy GR 
 
 TRUS GR 
Prostatectomy 
GR 1 2 3 Total 
1 2 1 0 3 
2 1 8 4 13 
3 0 1 4 5 

















MRI and CHOL 
PET 
1 1 > 1200 > 550 
2 2 850–1200 240–550 
3 3 < 850 < 240 
Abbreviations: GR, Gleason risk; TRUS, transrectal ultrasound; ADC, apparent diffusion 
coefficient; CHOL, 11C-choline; PET, positron emission tomography; SUVmax, maximum 




Fig. 1. The pathologist provided transverse sections of the prostatectomy specimens (A), 
which were co-registered with T2W MRI (B), forming fused images (C). Axial slices are also 
shown of co-registered DW MRI (D), CHOL PET (E) and FDG PET (F), zooming in on the 
prostate. A region of interest contour (yellow) was defined on the DW MRI and then the 
mean ADC was taken from this contour. A peripheral zone contour (green) was defined on 
the T2W MRI and then the SUVmax was taken from the co-registered CHOL PET and FDG 






Fig. 2. Scatter plots of the predictive test values (from (a) DW MRI, (b) CHOL PET, (c) FDG 
PET and (d) combination DW MRI / CHOL PET) versus the Gleason risk (GR). Where there 
is significant correlation or a trend towards correlation, a fitted regression line has been 
drawn. Horizontal lines have been drawn (corresponding to the cut-off values described in 






Fig. 3. Boxplot of the mean ADC in the region of interest (ROI) and the uninvolved 
peripheral zone (PZ) 
 
 
